Helicobacter pylori (HP infection has been identified as risk factor adenocarcinoma of the distal stomach. This cancer, which has its highest incidence in developing countries, is preceded by a sequence of histologic changes including chronic atrophic gastritis (CAG), intestinal metaplasia (IM), and dysplasia. Each step in the preneoplastic sequence increases risk for later development of malignancy. HP infection is often coincident with preneoplastic conditions but a causal association has not been proved. We hypothesize that CAG and some forms of IM indicate phenotypic but not genotypic mucosal change and that eradication of HP infection can revert gastric mucosal histology to normal epithelium. In order to evaluate this hypothesis, we intend to conduct a randomized, double-blind, placebo-control trial looking at the effect of HP eradication on gastric preneoplastic lesions. This study will be conducted in Chiapas, Mexico, a region with high rates of gastric cancer and preneoplasia. To identify subjects with CAG and/or IM, we will screen adults older than 40 years for serum pepsinogen levels. A ratio of pepsinogen I to pepsinogen II less than 5 will identify subjects to be enrolled in the endoscopy/treatment arm of the study. 300 subjects will undergo endoscopy. At endoscopy, the mucosa will be stained with methylene blue, a newly described marker for IM. Eight biopsies will be obtained and evaluated for histology and for HP infection. The subjects will then be randomized to receive two weeks of either omeprazole (20 mg BID) and amoxicillin (1 gm BID) or placebo. Six weeks following completion of the treatment, all subjects will again undergo endoscopy. Fifty subjects will also undergo a third endoscopy at the end of a year. Outcome measures will include: changes in histology (progression or reversion of Im and/or CAG), changes in IM phenotype (i.e., mucin type or Lewis antigen expression), changes in methylene blue mucosal staining and changes in pepsinogen level. We will also evaluate the value of methylene blue staining and pepsinogen testing in the identification of preneoplastic lesions. Gastric cancer is among the leading causes of cancer death worldwide. Unfortunately, studies evaluating the effect of HP eradication on gastric cancer incidence are too large and expensive to realistically undertake. Evidence that H. pylori therapy reverses preneoplastic lesions, however, could provide a foundation for gastric cancer screening and prevention trials as well as enhance understanding of preneoplasia and inflammation- related carcinogenesis.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA067488-04
Application #
2683606
Study Section
Special Emphasis Panel (SRC (24))
Program Officer
Hall, Leota
Project Start
1995-06-01
Project End
2001-03-31
Budget Start
1998-04-01
Budget End
2001-03-31
Support Year
4
Fiscal Year
1998
Total Cost
Indirect Cost
Name
Stanford University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
800771545
City
Stanford
State
CA
Country
United States
Zip Code
94305
Tsai, Chiaojung Jillian; Herrera-Goepfert, Roberto; Tibshirani, Robert John et al. (2006) Changes of gene expression in gastric preneoplasia following Helicobacter pylori eradication therapy. Cancer Epidemiol Biomarkers Prev 15:272-80
Ley, Catherine; Mohar, Alejandro; Guarner, Jeannette et al. (2004) Helicobacter pylori eradication and gastric preneoplastic conditions: a randomized, double-blind, placebo-controlled trial. Cancer Epidemiol Biomarkers Prev 13:4-10
Guarner, Jeannette; Herrera-Goepfert, Roberto; Mohar, Alejandro et al. (2003) Diagnostic yield of gastric biopsy specimens when screening for preneoplastic lesions. Hum Pathol 34:28-31
Goldman, Jonathan; Conrad, Donald F; Ley, Catherine et al. (2002) Validation of Spanish language dyspepsia questionnaire. Dig Dis Sci 47:624-40
Mohar, Alejandro; Ley, Catherine; Guarner, Jeannette et al. (2002) Eradication rate of Helicobacter pylori in a Mexican population at high risk for gastric cancer and use of serology to assess cure. Am J Gastroenterol 97:2530-5
Mohar, Alejandro; Ley, Catherine; Guarner, Jeannette et al. (2002) [High frequency of precancerous lesions of gastric cancer associated with Helicobacter pylori and response to treatment, in Chiapas, Mexico] Gac Med Mex 138:405-10
Ley, C; Mohar, A; Guarner, J et al. (2001) Screening markers for chronic atrophic gastritis in Chiapas, Mexico. Cancer Epidemiol Biomarkers Prev 10:107-12
Guarner, J; Herrera-Goepfert, R; Mohar, A et al. (2001) Gastric atrophy and extent of intestinal metaplasia in a cohort of Helicobacter pylori-infected patients. Hum Pathol 32:31-5
Guarner, J; Herrera-Goepfert, R; Mohar, A et al. (1999) Interobserver variability in application of the revised Sydney classification for gastritis. Hum Pathol 30:1431-4
Witherell, H L; Hiatt, R A; Replogle, M et al. (1998) Helicobacter pylori infection and urinary excretion of 8-hydroxy-2-deoxyguanosine, an oxidative DNA adduct. Cancer Epidemiol Biomarkers Prev 7:91-6